Riskpilot← Back to searchSign inGet full accessACD PHARMACEUTICALS AS
ASActiveOrg 979455518Lofoten Bio Centre Storeidøya 60, 8370 LeknesResearch and experimental development on natural sciences and engineering · NACE 7210Est. 199710 employees
Revenue 2024
NOK 24,7M
-16% vs 2023
EBITDA margin
-14.9%
-173% vs 2023
Equity ratio
18.5%
Financial strength
Net profit 2024
NOK -967K
-126% vs 2023
| Revenue | NOK 24,7M | -16% |
| EBITDA | NOK -3,7M | -173% |
| Net profit | NOK -967K | -126% |
| Total assets | NOK 75,4M | +129% |
| Equity | NOK 14M | -8% |
| Employees | 10 | — |
Legal name
ACD PHARMACEUTICALS AS
Org number
979455518
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30. juni 1997
Share capital
NOK 10 000 000
Employees
10 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Lofoten Bio Centre Storeidøya 60, 8370 Leknes
Phone
+4797650815
Email
post@acdpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 199 | 11 875 | 15 582 | 20 219 | 7 749 | 8 310 | 6 319 | 6 079 | 7 558 | 12 057 | 19 457 | 20 026 | 17 080 | 12 706 | 26 850 | 29 423 | 24 666 |
| Staff expenses | −978 | −910 | −984 | −1 559 | −1 915 | −2 660 | −4 022 | −3 267 | −3 601 | −2 680 | −4 209 | −3 923 | −105 | −4 581 | −14 282 | −10 411 | −9 331 |
| EBITDA | 1 865 | 2 640 | 3 208 | 2 809 | 2 009 | 1 727 | −1 378 | −1 993 | −821 | 3 241 | 9 383 | 10 229 | 11 356 | 1 319 | −15 860 | 5 022 | −3 671 |
| Depreciation & amort. | −8 | −7 | −7 | −7 | −7 | −6 | −2 | −2 | −2 | −10 | −10 | −28 | −34 | −34 | −97 | −174 | −153 |
| EBIT | 1 857 | 2 633 | 3 201 | 2 802 | 2 002 | 1 721 | −1 380 | −1 995 | −823 | 3 231 | 9 373 | 10 200 | 11 322 | 1 285 | −15 957 | 4 848 | −3 824 |
| Net financials | 63 | 4 | −58 | 42 | 27 | 180 | 1 379 | 942 | 169 | 1 628 | 4 622 | 2 234 | 201 | −26 | −36 | −469 | −717 |
| Profit before tax | 1 920 | 2 636 | 3 143 | 2 844 | 2 030 | 1 901 | −1 | −1 053 | −654 | 4 860 | 13 995 | 12 434 | 11 523 | 1 260 | −15 994 | 4 379 | −4 542 |
| Tax | 547 | 744 | 889 | 803 | 421 | 365 | −320 | −0 | −348 | 379 | 1 854 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 1 373 | 1 893 | 2 254 | 2 040 | 1 609 | 1 536 | 319 | −598 | −306 | 4 481 | 12 141 | 10 437 | 9 116 | 1 145 | −12 271 | 3 653 | −967 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 171 | 8 383 | 12 754 | 11 647 | 9 986 | 10 680 | 11 693 | 10 966 | 10 315 | 13 272 | 18 325 | 16 204 | 25 535 | 16 204 | 24 283 | 32 902 | 75 444 |
| Equity | 721 | 839 | 3 093 | 3 443 | 5 052 | 3 954 | 5 144 | 5 912 | 6 715 | 2 195 | 2 336 | 2 773 | 11 889 | 13 034 | 14 074 | 15 171 | 13 984 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 2 354 | 5 000 | 3 343 | 1 421 | 1 | 0 | 1 | 11 | 0 | 5 110 | 35 | 0 |
| Short-term debt | 3 450 | 7 544 | 9 662 | 8 204 | 4 934 | 4 372 | 1 549 | 1 711 | 2 179 | 11 076 | 15 989 | 13 430 | 13 636 | 3 171 | 5 099 | 17 696 | 61 461 |
| Total debt | 3 450 | 7 544 | 9 662 | 8 204 | 4 934 | 6 726 | 6 549 | 5 054 | 3 600 | 11 077 | 15 989 | 13 431 | 13 646 | 3 171 | 10 209 | 17 731 | 61 461 |
EBITDA margin
-14.9%
This company
15.8%
Market median
-194% vs market
20082024
Equity ratio
18.5%
This company
38.2%
Market median
-52% vs market
20082024
Return on equity
-6.9%
This company
18.4%
Market median
-138% vs market
20082024
Net profit margin
-3.9%
This company
8.1%
Market median
-148% vs market
20082024
Asset turnover
0.33×
This company
1.12×
Market median
-71% vs market
20082024
Debt / equity
4.40×
This company
0.62×
Market median
-610% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JR Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nordly Holding As | Company | 99.3% | 99.3% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pitancia As
ACD PHARMACEUTICALS AS Board members of ACD PHARMACEUTICALS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jim Roger Nordly | Chief Executive Officer | 0 companies |
| Paal Christian Krüger | Chairman | 0 companies |
| Lars Harry Vorland | Chairman | 0 companies |
| Tore Valderhaug | Board of Directors | 0 companies |
| Maria Strømme | Board of Directors | 0 companies |